GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » COGS-to-Revenue

CytoMed Therapeutics (CytoMed Therapeutics) COGS-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics COGS-to-Revenue?

CytoMed Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2023 was $0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.00 Mil.

CytoMed Therapeutics's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CytoMed Therapeutics's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

CytoMed Therapeutics COGS-to-Revenue Historical Data

The historical data trend for CytoMed Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics COGS-to-Revenue Chart

CytoMed Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
- - - -

CytoMed Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial - - - - -

CytoMed Therapeutics COGS-to-Revenue Calculation

CytoMed Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

CytoMed Therapeutics's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoMed Therapeutics  (NAS:GDTC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CytoMed Therapeutics's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CytoMed Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » COGS-to-Revenue
Comparable Companies
OKYO MTNB KA SPRB YS DYAI DTIL COYA AGLE IMUX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
F98:Germany
Address
1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544
Website
https://w2.cytomed.sg
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Executives
Chee Kong Choo director, 10 percent owner COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng director, officer: CSO and CMO 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang 10 percent owner 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan director, officer: Chief Operating Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd 10 percent owner 18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee director, officer: Chief Clinical Officer 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh director 1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544